美国食品药品监督管理局（FDA）已批准默沙东公司的帕博利珠单抗与紫杉醇联合用药方案，用于治疗铂类药物耐药的上皮性卵巢癌、输卵管癌以及原发性腹膜癌患者。此项批准为面临此类难治性癌症的患者提供了新的治疗选择。
美国食品药品监督管理局（FDA）已批准默沙东公司的帕博利珠单抗与紫杉醇联合用药方案，用于治疗铂类药物耐药的上皮性卵巢癌、输卵管癌以及原发性腹膜癌患者。此项批准为面临此类难治性癌症的患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.